Issue 140 • March 2024

Biotechs surf obesity drug wave to go beyond GLP-1RAs

As the market gets saturated by GLP-1 receptor agonists, companies investigate alternative approaches to treat obesity

Briefing

Novo Holdings acquires Catalent for $16.5bn

Feature

The opioid crisis: Different delivery systems tackle treatment needs

The Big Interview

Regulatory reform necessary to improve obesity drug access

Feature

The future of cell and gene therapy manufacturing

In association with

02/23/2024 20:50:43
  • Home | Biotechs surf obesity drug wave to go beyond GLP-1RAs
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • Bio Image Systems
  • phasetwo
  • In Depth
  • Biotechs surf obesity drug wave to go beyond GLP-1RAs
  • The opioid crisis: Different delivery systems tackle treatment needs
  • Pharma readies for climate disasters amidst supply chain concerns
  • CRISPR pipeline accelerates after milestone Casgevy approval
  • The future of cell and gene therapy manufacturing
  • Amgen showcases exciting potential in the obesity space at JPM24
  • Q&A: Regulatory reform necessary to improve obesity drug access
  • Novo to buy Catalent: The backlash begins
  • Sponsored Supplements
  • BEA Technologies
  • Listings
  • Events
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
02/22/2024 00:00:00